{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:27:00Z","timestamp":1786678020031,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002192","name":"LUNGevity Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtocrr.2026.101036","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T15:36:55Z","timestamp":1781537815000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion\u2013Positive NSCLC Real-World Cohort: A Brief Report"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1387-3433","authenticated-orcid":false,"given":"Alvaro Guimaraes","family":"Paula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Concannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir Y.","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny V.","family":"Pozadzides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waree","family":"Rinsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Guimaraes","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don L.","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique B.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8942","authenticated-orcid":false,"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101036_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2026.101036_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101036_bib4","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib5","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II Trial","volume":"43","author":"Gautschi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jtho.2022.12.018","article-title":"RET-MAP: An international multicenter study on clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion","volume":"18","author":"Aldea","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib7","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2026.101036_bib9","doi-asserted-by":"crossref","first-page":"S824","DOI":"10.1016\/j.annonc.2024.08.1352","article-title":"EP0031 a next-generation selective RET inhibitor (SRI): correlation of molecular and clinical responses in patients with RET alteration positive solid tumours na\u00efve to or following prior SRI","volume":"35","author":"Garralda","year":"2024","journal-title":"Annal Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib10","series-title":"NCCN clinical practice guidelines in oncology for non-small cell lung cancer","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.101036_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105807","article-title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","volume":"10","author":"Peled","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2026.101036_bib12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2025.7071","article-title":"Efficacy and safety of continuing next-generation ALK TKIs with chemotherapy for advanced ALK-positive NSCLC: a multicenter retrospective study","volume":"23","author":"Waliany","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtocrr.2026.101036_bib13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2217\/imt-2021-0035","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer","volume":"13","author":"Bhandari","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtocrr.2026.101036_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2026.101036_bib15","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2020.02.006","article-title":"Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: a multicenter retrospective study","volume":"21","author":"Shen","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101036_bib16","first-page":"75","article-title":"LIBRETTO-431: confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET+) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC","volume":"15","author":"Lee","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.jtocrr.2026.101036_bib17","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101036_bib18","doi-asserted-by":"crossref","first-page":"10041","DOI":"10.1007\/s00432-023-04924-7","article-title":"TP53 or CDKN2A\/B covariation in ALK\/RET\/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis","volume":"149","author":"Jiang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101036_bib19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:31:49Z","timestamp":1786674709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666364326000871"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101036","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion\u2013Positive NSCLC Real-World Cohort: A Brief Report","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}